bd means once a day in medical term.
bd means once a day in medical term.
meaning of bd in medical term?
once a day
Na
Na
in 1999, as bd passed more than 100 years of presence in the medical devices industry, bd announced its new corporate identity. numerous independent brand names were replaced by a single name: bd. in addition, the company symbol that is used today was introduced. bd also named edward j. ludwig as the company's president. ludwig was also named chief executive officer (2000) and chairman of the board of directors (2002). on february 9, 1999, bd announced the acquisition of biometric imaging, inc. (bmi), a privately held company serving the transfusion medicine, infectious diseases, and oncology markets. on december 20, 2000, bd signed an agreement to acquire gentest corporation, a privately held company serving the life sciences market in the areas of drug metabolism and toxicology testing of pharmaceutical candidates. during that time, bd also got heavily involved in global health issues announcing a five-year maternal and neonatal tetanus worldwide elimination partnership with unicef (1999), launching the bd safety compliance initiative (2000), and pledging $1 million contribution to the international aids vaccine initiative (2002.) in 2003 and 2004, bd introduced several innovative products: bd facsaria cell sorter—the first entirely new instrument in the next-generation portfolio of flow cytometers (2003), bd accuspray—a nasal drug delivery system for administering vaccines (2003), bd.id—a patient identification system designed to limit the potential for medical errors in specimen collection (2003), and the world's first "intelligent" insulin pump and glucose monitoring system, a wireless system consisting of a medtronic minimed paradigm 512 insulin pump and paradigm link blood glucose monitor, co-developed with bd. in the beginning of the 21st century bd also invested in growing its business by acquiring several strategically important companies. in 2001, it acquired the gentest corporation, a leading in drug metabolism and toxicology testing company. in 2004, bd completed the acquisition of atto bioscience acquired, a company specializing in optical instrumentation, software, and reagents for real-time analysis of interactions taking place in living cells. in 2005 bd entered the field of proteomics through its acquisition of ffe weber gmbh, which specialized in the separation and fractionation of complex proteins. 2006 was also an important year to document bd's growth as the company acquired geneohm sciences—a leader in the development of molecular diagnostic testing for the rapid detection of bacterial organisms and tripath imaging, a cancer diagnostics company.
becton dickinson